This database contains 105 studies, archived under the term: "metabolism"
Click here to filter this large number of results.
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]
Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial
Akhondzadeh, S.,
Sabet, M. Shafiee,
Harirchian, M. H.,
Togha, M.,
Cheraghmakani, H.,
Razeghi, S.,
Hejazi, S. Sh,
Yousefi, M. H.,
Alimardani, R.,
Jamshidi, A.,
Zare, F.,
Moradi, A.
What Is Known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD).; Objective: The goal of this study was to […]
Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial
Cukierman-Yaffe, Tali,
Gerstein, Hertzel C.,
Williamson, Jeff D.,
Lazar, Ronald M.,
Lovato, Laura,
Miller, Michael E.,
Coker, Laura H.,
Murray, Anne,
Sullivan, Mark D.,
Marcovina, Santica M.,
Launer, Lenore J.
Objective: Diabetes is associated with cognitive decline and dementia. However, the relationship between the degree of hyperglycemia and cognitive status remains unclear. This was explored using baseline cognitive measures collected in the ongoing Memory in Diabetes (MIND) substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.; Research Design and Methods: The relationship […]
Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer’s disease
Baker, Laura D.,
Frank, Laura L.,
Foster-Schubert, Karen,
Green, Pattie S.,
Wilkinson, Charles W.,
McTiernan, Anne,
Cholerton, Brenna A.,
Plymate, Stephen R.,
Fishel, Mark A.,
Watson, G. Stennis,
Duncan, Glen E.,
Mehta, Pankaj D.,
Craft, Suzanne
Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. Although the benefits of aerobic exercise for physical health are well-documented, exercise effects on cognition have not been examined for older adults with poor glucose regulation associated with prediabetes […]
Effects of aerobic exercise on mild cognitive impairment: a controlled trial
Baker, Laura D.,
Frank, Laura L.,
Foster-Schubert, Karen,
Green, Pattie S.,
Wilkinson, Charles W.,
McTiernan, Anne,
Plymate, Stephen R.,
Fishel, Mark A.,
Watson, G. Stennis,
Cholerton, Brenna A.,
Duncan, Glen E.,
Mehta, Pankaj D.,
Craft, Suzanne
Objectives: To examine the effects of aerobic exercise on cognition and other biomarkers associated with Alzheimer disease pathology for older adults with mild cognitive impairment, and assess the role of sex as a predictor of response.; Design: Six-month, randomized, controlled, clinical trial.; Setting: Veterans Affairs Puget Sound Health Care System clinical research unit.; Participants: Thirty-three […]
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]
Improved cognitive-cerebral function in older adults with chromium supplementation
Insulin resistance is implicated in the pathophysiological changes associated with Alzheimer’s disease, and pharmaceutical treatments that overcome insulin resistance improve memory function in subjects with mild cognitive impairment (MCI) and early Alzheimer’s disease. Chromium (Cr) supplementation improves glucose disposal in patients with insulin resistance and diabetes. We sought to assess whether supplementation with Cr might […]